Advertisement

Transmembrane Signaling by Receptor Oligomerization

Protocol
Part of the Methods In Molecular Biology™ book series (MIMB, volume 84)

Abstract

The coordmation of cell growth, differentiation, and other activities in a multicellular organism is precisely controlled by a plethora of growth factors or cytokines that achieve then effects upon the cell by binding to specific cell-surface receptors. The majority of these numerous receptors for growth factors and cytokines are bitopic integral-membrane proteins that contain an extracellular ligand-binding domain; a single transmembrane domain that is assumed to be an α-helix; and a cytoplasmic-effector domain (1,2). The cytoplasmic- effector domain may have enzymatic activity, as is the case for the growth-factor receptor tyrosine kinases (1); or it may require interaction with other cytoplasmic-signaling molecules—notably the Janus (JAK) kinases in the case of the cytokine-receptor superfamily (2,3). Over the years, several mechanisms have been suggested for how such bitopic-membrane proteins can transmit signals across the cell membrane upon binding of their cognate ligand (4). Intramolecular mechanisms that have been proposed involve ligand-induced conformational changes that are propagated through the single transmembrane α-helix or alter the association of the receptor with the membrane (a “push-pull” model). Objections to these models are based upon the stability of fully hydrogen-bonded transmembrane α-helices and the ease of deformability of a lipid bilayer. Any alteration in the membrane-spanning helix is likely to be “damped” by the readily deformable membrane that it spans (see ref. 4 for a discussion). In the late 1970s studies employing fluorescence-photobleaching recovery demonstrated that several growth factors, most notably epidermal-growth factor (EGF), induce ohgomerization of their specific receptors (5), and that this is necessary for a biological response (6). Yarden and Schlessinger subsequently showed that the purified EGF receptor tyrosme kinase undergoes dimerization upon binding to EGF (7), and that the dimeric form of the receptor displays elevated tyrosme kinase activity (8). EGF-induced EGF-receptor dimerization was also demonstrated in intact cells, using chemical crosslinking approaches (9,10). As a result of these observations, a model for signal transduction by allosteric receptor oligomerization was proposed (11). This model has since been confirmed for many receptor tyrosine kinases in addition to the EGF receptor, as well as for many of the cytokine receptors. The general ohgomerization model holds that inactive receptor monomers are in equilibrium with active receptor dimers such that, in the absence of ligand, the eqmhbrium greatly favors the monomeric form. Upon ligand binding, the equilibrium is shifted in favor of the activated dimer (which may be a homo- or heterodliner), with resultant biological effects. In the past 10 yr, our understanding of this process has developed greatly. Where tyrosine kinase activity is a property of the receptor (the receptor tyrosme kinases) or is associated with the receptor (as with JAK kinases bound to cytokine receptors), it appears that ligand-induced receptor oligomerization brings kinase molecules into close proximity such that they can phosphorylate one another. This trans-phosphorylation, together with additional possible conformational alterations upon ohgomerization, leads to stimulation of the kinase activity—coupling receptor oligomerization to receptor activation. In this chapter, we will concentrate primarily on the mechanistic aspects of ligand-induced receptor oligomerization, selecting examples for which the process has been most thoroughly studied. A common theme emerges from these studies, in which multivalent ligand binding provides the driving force to shift the monomer/oligomer equilibrium in favor of the oligomer. There are several variations on this common theme, which appear to be exploited to enhance signal diversity for a given combination of ligands and receptors. Details of the protein-protein interactions that are involved in coupling receptor activatron to the downstream-signaling cascades are discussed in the previous two chapters by Kuriyan and Mayer, respectively.

Keywords

Extracellular Domain Tumor Necrosis Factor Receptor Cytokine Receptor Receptor Molecule Autophosphorylation Site 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Ullrich A and Schlessinger J. (1990) Signal transduction by receptors with tyrosme kinase activity Cell 61, 203–212.PubMedCrossRefGoogle Scholar
  2. 2.
    Ktshtinoto T, Taga T., and Aktra S (1994) Cytokme signal transduction Cell 76, 252–262Google Scholar
  3. 3.
    Ihle J. N (1995) Cytokme receptor signaling Nature 377, 591–594PubMedCrossRefGoogle Scholar
  4. 4.
    Bormann B. J. and Engelman D M. (1992) Intramembrane helix-helix assoctanon in oligomerization and transmembrane signaling Ann Rev Biophys Biomol Struct 21, 223–242.CrossRefGoogle Scholar
  5. 5.
    Schlessinger J (1978) in Cell Surface Events in Cellular Regulation (DeLisi C. and Blumenthal R., eds.), Elsevier, North Holland, 89–111.Google Scholar
  6. 6.
    Schechter Y, Hernaez L., Schlessinger J., and Cuatrecasas P. (1979) Local aggregation of hormone-receptor complexes is required for activation by epidermal growth factor. Nature 278, 835–838.PubMedCrossRefGoogle Scholar
  7. 7.
    Yarden Y. and Schlessinger J. (1987) Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor Biochemistry 26, 1443–1451.PubMedCrossRefGoogle Scholar
  8. 8.
    Yarden Y and Schlessinger J. (1987) Self-phosphorylation of epidermal growth factor receptor Evidence for a model of intermolecular allostertc activation. Biochemistry 26, 1434–1442PubMedCrossRefGoogle Scholar
  9. 9.
    Fanger B. O., Austin K S, Earp H. S, and Ctdlowski J. A. (1986) Cross-linking of epidermal growth factor receptors in intact cells. Detection of initial stages of receptor clustering and determination of molecular weight of high-affinity receptors. Biochemistry 25, 6414–6420PubMedCrossRefGoogle Scholar
  10. 10.
    Cachet C., Kashles 0, Chambaz E. M., King C. R., and Schlessinger J (1988) Demonstration of eptdermal growth factor-induced receptor olierization in living cells using a chemical covalent cross-linking agent. J Biol Chem 263, 3290–3295.Google Scholar
  11. 11.
    Schlessinger J (1988) Signal transduction by allostertc receptor oligomerization Trends Biochem Sci 13, 443–447.PubMedCrossRefGoogle Scholar
  12. 12.
    Taga T. and Kishimoto T. (1993) Cytokine receptors and signal transduction FASEB J 7, 3387–3396.Google Scholar
  13. 13.
    Sprang S. R. and Bazan J. F. (1993) Cytokme structural taxonomy and mechanisms of receptor engagement. Curr Open Struct Biol 3, 815–827.CrossRefGoogle Scholar
  14. 14.
    Bazan J.F. (1990) Haemopoietic receptors and hellcal cytokmes Immunol Today 11, 350–354PubMedCrossRefGoogle Scholar
  15. 15.
    Cunningham B C, Ultsch M, de Vos A. M., Mulkerrm M. G., Clauser K. R, and Wells J. A. (1991) Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 254, 821–825PubMedCrossRefGoogle Scholar
  16. 16.
    de Vos A. M., Ultsch M., and Kossiakoff A A (1992) Human growth hormone and extracellular domain of its receptor. crystal structure of the complex Scwnce 255, 306–312.CrossRefGoogle Scholar
  17. 17.
    Fuh G, Cunningham B. C, Fukunaga R., Nagata S, Goeddel D. V, and Wells J A. (1992) Rational design of potent antagomsts to the human growth hormone receptor. Science 256, 1677–1680PubMedCrossRefGoogle Scholar
  18. 18.
    Kossiakoff A. A, Somers W., Ultsch M, Andow K., Muller Y A, and de Vos A. M. (1994) Comparison of the intermediate complexes of human growth hormone bound to the human growth hormone and prolactin receptors. Prot Sci 3, 1697–1705.CrossRefGoogle Scholar
  19. 19.
    Philo J. S, Aoki K. H., Arakawa T, Narhi L 0, and Wen J (1996) Dimerizanon of the extracellular domain of the erythropoietin (EPO) receptor by EPO One high-affinity and one low-affinity interaction. Biochemistry 35, 1681–1691.PubMedCrossRefGoogle Scholar
  20. 20.
    Horan T, Wen J, Narhi L, Parker V., Garcia A., Arakawa T, and Philo J (1996) Dimerization of the extracellular domain of granulocyte-colony stimulating factor receptor by llgand binding. A monovalent ligand induces 2 2 complexes Biochemistry 35, 4886–4896.PubMedCrossRefGoogle Scholar
  21. 21.
    Hnaoka 0, Anaguchi H., Asakura A, and Ota Y (1995) Requirement for the immunoglobulin-like domain of granulocyte colony-stimulating factor receptor in formation of a 2 1 receptor-ligand complex. J Biol Chem 270, 25,928–25,934CrossRefGoogle Scholar
  22. 22.
    Robmson R. C., Grey L. M., Staunton D, Vankelecom H, Vernalhs A. B, Moreau J.-F., Stuart D I, Heath J K, and Jones E. Y (1994) The crystal structure of leukemia inhibitory factor Implications for receptor binding Cell 77, 1101–1116CrossRefGoogle Scholar
  23. 23.
    Paonessa G., Graziam R., De Servo A., Savmo R, Ciappom L., Lahm A., Salvati A L, Tomatti C, and Cihberto G. (1995) Two distinct and independent sites on IL-6 trigger gp130dimer formation and signaling EMBOJ 14, 1942–1951Google Scholar
  24. 24.
    Ward L. D, Howlett G. J, Discolo G., Yasukawa K., Hammacher A., Moritz R., and Simpson R J (1994) High affinity interleukm-6 receptor is a hexameric complex consisting of two molecules each of interleukm-6, interleukm-6 receptor and gp130 J Biol Chem 269, 23,286–23,289.PubMedGoogle Scholar
  25. 25.
    Stahl N. and Yancopoulos G. D. (1993) The alphas betas, and kinases of cytokme receptor complexes Cell 74, 587–590PubMedCrossRefGoogle Scholar
  26. 26.
    Walter M. R., Windsor W T, Nagabhushan T. L., Lundell D. J., Lunn C. A., Zauodny P J., and Narula S K. (1995) Crystal structure of a complex between interferon-γ and its soluble high-affinity receptor. Nature 376, 230–235.PubMedCrossRefGoogle Scholar
  27. 27.
    Loetscher H. R., Gentz R., Zulauf M., Lustig A, Tabuchi H., Schlaeger E J, Brockhaus M., Gallati H., Maanneberg M., and Lesiauer W. (1991) Recombr-nant 55 kDa TNF receptor Stoichiometry of binding to TNFa and TNFβ and inhibition of TNF activity. J Biol. Chem 266, 18,324–18,329.PubMedGoogle Scholar
  28. 28.
    Banner D. W., D’Arcy A., Janes W., Gentz R., Schoenfeld H.-J., Broger C., Loetscher H., and Lesslauer W. (1993) Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implinations for TNF receptor activation. Cell 73, 43l–445CrossRefGoogle Scholar
  29. 29.
    Ward C. W., Hoyne P A., and Flegg R. H. (1995) Insulin and epidermal growth factor receptors contam the cysteme repeat motif found in the tumor necrosis factor receptor. Proteins Struct, Funct, and Genet 22, 141–153CrossRefGoogle Scholar
  30. 30.
    Tartagha L A and Goeddel D. V. (1992) Tumor necrosts factor signaling: A dominant negative mutation supresses the activation of the 55 kDa tumor necrosis factor receptor. J Biol Chem 267, 4304–4307.Google Scholar
  31. 31.
    Engelmann H, Holtinan H., Brakebusch C, Avni S. Y, Sarov I., Nophar Y, Hadas E., Leitner O., and Wallach D. (1990) Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol. Chem 265, 14,497–14,504.PubMedGoogle Scholar
  32. 32.
    Baker S. J. and Reddy E P (1996) Transducers of life and death TNF receptor superfamily and associated proteins. Oncogene 12, 1–9.PubMedGoogle Scholar
  33. 33.
    Canals F. (1992) Signal transmission by epidermal growth factor receptor Coincidence of activation and olirierization Biochemistry 31, 4493–4501PubMedCrossRefGoogle Scholar
  34. 34.
    Ullrich A. and Schlessinger J. (1990) Signal transduction by receptors with tyrosme kinase activity Cell 61, 203–212PubMedCrossRefGoogle Scholar
  35. 35.
    Schlessinger J. and Ullrmh A. (1992) Growth factor signaling by receptor tyrosme kinases. Neuron 9, 383–391.PubMedCrossRefGoogle Scholar
  36. 36.
    Kashles O., Yarden Y., Fischer R., Ullrich A, and Schlessinger J. (1991) A dominant negative mutation suppresses the function of normal eprdermal growth factors by heterodimerization. Mol Cell. Biol 11, 1454–1463.PubMedGoogle Scholar
  37. 37.
    Ueno H, Colbert H., Escobedo J. A., and Williams L. T. (1991) Inhibition of PDGFβ receptor signal transduction by coexpression of a truncated receptor. Science 252, 844–848.PubMedCrossRefGoogle Scholar
  38. 38.
    Amaya E., Musci T. J., and Kirschner M. W (1991) Expression of a dominant negative mutant of the FGF receptor disrupts mesoderm formation in Xenopus embryos. Cell 66, 257–270PubMedCrossRefGoogle Scholar
  39. 39.
    Werner S., Wemberg W, Liao X., Peters K. G., Blessing M, Yuspa S, Werner R. L., and Willlams L T (1993) Targeted expression of a dommant-negative FGF receptor mutant in the epidermis of transgemc mice reveals a role for FGF in keratinocyte organization and differentiation. EMBO J 12.Google Scholar
  40. 40.
    Millauer B, Shawyer L K, Plate K. H, Risau W., and Ullrich A. (1994) Glio-blastoma growth inhibited in vivo by a dominant-negative FLK-1 mutant. Nature 367, 576–579.PubMedCrossRefGoogle Scholar
  41. 41.
    Murillas R, Larcher F, Conti C J, Santos M., Ullrmh A., and Jorcano J. L (1995) Expression of a dominant negative mutant of eprdermal growth factor receptor in the epidermis of transgemc mice elicits striking alterations in hair follicle development and skm structure EMBOJ 14, 5216–5223Google Scholar
  42. 42.
    Riedel H., Dull T J, Schlessinger J, and Ullrich A. (1986) A chimaeric receptor allows insulin to stimulate tyrosme kinase activity of epidermal growth factor Nature 324, 68–70.PubMedCrossRefGoogle Scholar
  43. 43.
    Oefner C, D’Arcy A., Wmkler F K., Eggimann B, and Hosang M (1992) Crystal structure of human platelet-derived growth factor BB. EMBO J 11, 3921–3926.PubMedGoogle Scholar
  44. 44.
    Heldm C.-H., Ernlund A., Rorsman C., and Ronnstrand L (1989) Dimerization of B-type platelet-derived growth factor receptors occurs after ligand binding and is closely associated with receptor kinase activation. J Biol Chem 264, 8905–8912Google Scholar
  45. 45.
    Herren B., Rooney B., Weyer K. A., Iberg N, Schmid G, and Pech M (1993) Dimerization of extracellular domains of platelet-derived growth factor receptors: A revised model of receptor-ligand interaction J Biol Chem 268, 15,088–15,095PubMedGoogle Scholar
  46. 46.
    Vassbotn F S., Andersson A., Westermark B, Heldm C.-H., and Ostinan A (1993) Reversion of autocrme transformation by a dominant negative platelet-derived growth factor mutant. Mol Cell Biol 13, 4066–4076.PubMedGoogle Scholar
  47. 47.
    Fretto L J., Snape A. J., Tomlinson J E, Seroogy J J, Wolf D. L., LaRochelle W. J., and Geese N A. (1993) Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB binding to α and β PDGF receptor. J Biol Chem. 268, 3625–3631.PubMedGoogle Scholar
  48. 48.
    Blechman J. M., Lev S., Brizzi M. F., Leitner O., Pegoraro L., Givol D, and Yarden Y. (1993) Soluble c-Kit proteins and antrreceptor monoclonal antibodies confine the binding site of the stem cell factor. J Biol Chem 268, 4399–4406.PubMedGoogle Scholar
  49. 49.
    Lev S., Blechman J., Nishikawa S-1, Givol D., and Yarden Y. (1993) Interspecies molecular chimeras of Kit help define the binding site of the stem cell factor Mol Cell Biol 13, 2224–2234.PubMedGoogle Scholar
  50. 50.
    Lev S., Yarden Y., and Givol D. (1992) A recombinant ectodomain of the receptor for the stem cell factor (SCF) retains ligand-induced receptor dimerization and antagonizes SCF-stimulated cellular responses. J Biol Chem 267, 10,86–10,873.Google Scholar
  51. 51.
    Lev S, Yarden Y., and Givol D. (1992) Dimerization and activation of the Kit receptor by monovalent and bivalent binding of the stem cell factor. J Biol Chem 267, 15,970–15,977PubMedGoogle Scholar
  52. 52.
    Philo J. S., Wen J, Schwartz M G, Mendiaz E A, and Langley K. E (1996) Human stem cell factor dimer forms a complex with two molecules of the extracellular domain of its receptor, Kit. J Biol Chem 271, 6895–6902.PubMedCrossRefGoogle Scholar
  53. 53.
    Lemmon M. A., Pmchasi D, Zhou M, Lax I, and Schlessinger J. (1997) Dimerization of Kit is driven by bivalent binding of stem cell factor. J Biol Chem 272, 6311–6317PubMedCrossRefGoogle Scholar
  54. 54.
    Blechman J M., Lev S, Barg J, Eisenstem M, Vaks B, Vogel Z., Givol D., and Yarden Y (1995) The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction Cell 80, 103–113PubMedCrossRefGoogle Scholar
  55. 55.
    Philo J, Talvenhermo J, Wen J, Rosenfeld R, Welcher A, and Arakawa T (1994) Interactions of neurotrophm-3 (NT-3), brain-derived neurotrophic factor (BDNF), and the NT3-BDNF heterodimer with the extracellular domain of the TrkB and TrkC receptors J Biol Chem 269, 27,840–27,846.PubMedGoogle Scholar
  56. 56.
    Davrs S, Gale N. W., Aldrrch T H, Marsonprerre P C, Lhotak V, Pawson T., Goldfarb M., and Yancopoulos G. D. (1994) Lrgands for EPH-related receptor tyrosme kinases that require membrane attachment or clustering for activity. Science 266, 816–819.CrossRefGoogle Scholar
  57. 57.
    Rapraeger A C., Krufka A, and Olwin B B (1991) Requirement of heparan sulfate for bFGF-mediated frbroblast growth and myoblast drfferentratron Science 252, 1705–1708PubMedCrossRefGoogle Scholar
  58. 58.
    Yayon A, Klagsbrun M, Esko J D., Leder P, and Orintz D M (1991) Cell-surface heparm-like molecules are required for binding of bFGF to its high-affinity receptor. Cell 64, 841–848PubMedCrossRefGoogle Scholar
  59. 59.
    Orintz D. M., Yayon A., Flanagan J. G., Svahn C. M., Levi E., and Leder P. (1992) Heparm is required for cell-free binding of bFGF to a soluble receptor and for mrtogenests in whole cells. Mel Cell Biol 12, 240–247.Google Scholar
  60. 60.
    Mach H., Volkm D. B., Burke C. J., Mrddaugh C. R., Lmhardt R. J., Fromm J. R., Loganathan D., and Mattsson L (1993) Nature of the interactron of heparm wrth aFGF. Biochemistry 32, 5480–5489.PubMedCrossRefGoogle Scholar
  61. 61.
    Sprvak-Kroizman T, Lemmon M A, Diukic I, Ladbury J E, Pinchasr D, Huang J, Jaye M., Crumley G, Schlessinger J, and Lax I. (1994) Heparm-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, actrvatron, and cell prolrferatron. Cell 79, 1015–1024.CrossRefGoogle Scholar
  62. 62.
    Klagsbrun M and Band A (1991) A dual receptor system IS required for bFGF activity. Cell 67, 229–231PubMedCrossRefGoogle Scholar
  63. 63.
    Schlessinger J., Lax I., and Lemmon M A. (1995) Regulation of growth factor activation by proteoglycans What is the role of the low affinity receptors? Cell 83, 367–360CrossRefGoogle Scholar
  64. 64.
    Kan M., Wang F., Xu J., Crabb J. W., Hou J., and McKeehan W. L. (1993) An essentral heparm-binding domain in the frbroblast growth factor receptor kinase. Science 259, 1918–1921PubMedCrossRefGoogle Scholar
  65. 65.
    Zhu X., Hsu B. T., and Rees D. C (1993) Structural studies of the anti-ulcer drug sucrose octasulfate bound to acidic frbroblast growth factor receptor. Structure 1, 27–34PubMedCrossRefGoogle Scholar
  66. 66.
    Faham S, Hrleman R. E., Fromm J R., Lmhardt R. J., and Rees D. C. (1996) Heparin structure and interactions with basic frbroblast growth factor. Science 271, 1116–1120PubMedCrossRefGoogle Scholar
  67. 67.
    Lemmon M A, Bu Z, Ladbury J. E., Pmchasr D., Zhou M., Lax I., Engelman D M, and Schlessinger J (1997) Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J 16, 28l–294.CrossRefGoogle Scholar
  68. 68.
    Lax I, Mitra A. K., Ravera C., Hurwitz D R, Rubmstem M, Ullrrch A, Stroud R M, and Schlessinger J (1991) Eprdermal growth factor (EGF) induces oligomerization of soluble, extracellular, ligand-binding domain of EGF receptor. J Biol Chem 266, 13,828–13,833.PubMedGoogle Scholar
  69. 69.
    Gunther N., Beizel C., and Weber W. (1990) The secreted form of the epidermal growth factor receptor Characterization and crystallization of the receptor-ligand complex J Biol Chem 265, 22,082–22,085PubMedGoogle Scholar
  70. 70.
    Weber W., Bertics P. J., and Gill G. N. (1984) Immunoaffinity purtfication of the epidermal growth factor receptor. Stoinhiometry of binding and kinetics of self-phosphorylation. J Biol Chem 259, 14,631–14,636.PubMedGoogle Scholar
  71. 71.
    Sherrill J M and Kyte J (1996) Activation of epidermal growth factor receptor by epidermal growth factor Biochemistry 35,.5705–5718PubMedCrossRefGoogle Scholar
  72. 72.
    Lax I., Burgess W. H., Bellot F, Ullrtch A., Schlessinger J., and Givol D (1988) Localization of a maJor receptor-binding domain for eptdermal growth factor by affinity labeling Mol Cell Biol 8, 1831–1834PubMedGoogle Scholar
  73. 73.
    Lax I., Bellot F., Howk R., Ullrmh A., Gtvol D., and Schlessinger J (1989) Functional analysis of the ligand binding site of EGF-receptor utiling chicken/ human receptor molecules. EMBO J 8, 421–427PubMedGoogle Scholar
  74. 74.
    Woltjer R. L, Lukas T. L., and Staros J. V. (1992) Direct identification of residues of the eptdermal growth factor receptor in close proximity to the ammo terminus of bound eptdermal growth factor. Proc Natl Acad Sci USA 89, 7801–7805.PubMedCrossRefGoogle Scholar
  75. 75.
    Kohda D., Odaka M., Lax I., Kawasaki H., Suzuki K, Ullrtch A., Schlessinger J., and Inagaki F. (1993) A 40-kDa epidermal growth factor/transforming growth factor α-binding domain produced by limited proteolysis of the extracellular domain of the epidermal growth factor receptor J Biol Chem 268, 1976–1981PubMedGoogle Scholar
  76. 76.
    Tanigucht T. (1995) Cytokme signaling through nonreceptor protein tyrosme kinases. Science 268, 25l–255.Google Scholar
  77. 77.
    Honegger A. M, Schintdt A., Ullrtch A., and Schlessinger J. (1990) Evidence for epidermal growth factor (EGF)-induced intermolecular autophosphorylation of the EGF receptors in living cells. Mel Cell Biol 10, 4035–4044.Google Scholar
  78. 78.
    Hubbard S. R, Wet L., Ellis L., and Hendrtckson W. A. (1994) Crystal structure of the tyrosme kinase domain of the human insulin receptor Nature 372, 746–754PubMedCrossRefGoogle Scholar
  79. 79.
    Pawson T. (1995) Protein modules and signaling networks Nature 373, 573–580.PubMedCrossRefGoogle Scholar
  80. 80.
    Claesson-Welsh L. (1994) Platelet-dertved growth factor receptor signals. J Biol Chem 269, 32,023–32,026.PubMedGoogle Scholar
  81. 81.
    Kanakaraj P., Raj S, Khan S. A., and Btshayee S. (1991) Ltgand-induced interaction between a-and α-type platelet-derived growth factor (PDGF) receptors’ Role of receptor heterodimers in kinase activation. Biochemistry 30, 1761–1767PubMedCrossRefGoogle Scholar
  82. 82.
    Rupp E, Siegbahn A., Ronnstrand L., Wernstedt C., Claesson-Welsh L, and Heldm C-H (1994) A unique autophosphorylation site in the platelet-derived growth factor α receptor from a heterodimeric receptor complex Eur J Biochem 225, 29–41PubMedCrossRefGoogle Scholar
  83. 83.
    King C R, Borrello I, Bellot F, Comoglio P., and Schlessinger J. (1988) EGF binding to its receptor trtggers a rapid tyrosme phosphorylation of the erbB2 protein in the mammary tumor cell line SKBR-3. EMBO J 7, 1647–1651PubMedGoogle Scholar
  84. 84.
    Stern D. F and Kamps M P. (1988) EGF-stimulated tyrosme phosphorylation of p1 85new A potential model for receptor interactions EMBO J 7, 995–1001PubMedGoogle Scholar
  85. 85.
    Sprvak-Krotzman T, Rotin D., Pmchasr D., Ullrtch A., Schlessinger J, and Lax I. (1992) Heterodimerization of c-erbB2 with different eptdermal growth factor receptor mutants ehcrts stimulatory or mhtbrtory responses. J Biol. Chem 267, 8056–8063.Google Scholar
  86. 86.
    Wada T., Qian X., and Greene M I (1990) Intermolecular assoctatron of the p185new protein and EGF modulates EGF receptor function. Cell 61, 1339–1347.PubMedCrossRefGoogle Scholar
  87. 87.
    Soltoff S. P., Carraway K L, Prrgent S A, Gulhck W. G., and Cantley L C (1994) ErbB3 is involved in activation of phosphatidylinosrtol 3-kinase by epidermal growth factor Mol Cell Biol 14, 3550–3558.PubMedGoogle Scholar
  88. 88.
    Reese D. J II, van Raaij T M, Plowman G D, Andrews G. C, and Stern D F. (1995) The cellular response to neuregulins IS governed by complex interactions of the erbB receptor family. Mel Cell Biol 15, 5770–5776.Google Scholar
  89. 89.
    Riese D. J II, Bermingham Y., van Raatj T. M, Buckley S, Plowman G D, and Stern D. F. (1996) Betacellulin activates the eptdermal growth factor and erbB4, and induces cellular response patterns distinct from those stimulated by eprdermal growth factor of neuregulin β Oncogene 12, 345–353PubMedGoogle Scholar
  90. 90.
    Beerh R. R. and Hynes N. E. (1996) Eptdermal growth factor-related peptrdes activate distinct subsets of erbB receptors and differ in their brologrcal actrvmes. J Biol. Chem 271, 6071–6076CrossRefGoogle Scholar
  91. 91.
    Pinkas-Kramarski R, Soussan L, Waterman H., Levkowrtz G, Alroy I, Klapper L, Lavi S., Seger R., Raizkm B. J., Sela M, and Yarder Y. (1996) Diversification of Neu drfferentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15, 2452–2467.PubMedGoogle Scholar
  92. 92.
    Nicholls A. and Hoing B J (1991) A rapid finite difference algorithm, utilizing successive over-relaxation to solve the Poisson-Bolizmann equation. J Comp Chem. 12, 11,715–11,718CrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 1998

Authors and Affiliations

  1. 1.Department of Biochemistry and BiophysicsUniversity of Pennsylvania School of MedicinePhiladelphia
  2. 2.Department of PharmacologyNew York University Medical CenterNew York

Personalised recommendations

Cite protocol

Buy options